The Devastating Impact of Missing Puberty - James Linehan (#5)
20 March 2025
With James Linehan
Global
James Linehan was born with hypogonadism, a condition that prevented him from going through puberty naturally. His account of the resulting emotional immaturity, social isolation, and lasting health consequences — including irreversible fertility damage — bears directly on current UK policy debates. The Cass Review found insufficient evidence that puberty blockers are safe or reversible. Linehan's lived experience corroborates those conclusions from the perspective of someone who has lived without puberty for years, offering a unique lens on what is being withheld from gender-questioning children placed on GnRH analogues.
James Linehan was not placed on puberty blockers by a gender clinic — he was born with hypogonadism, a hormonal condition that prevented his body from triggering puberty naturally. That distinction makes his testimony unusually significant. He is not speaking as an outside critic but as someone who lived for years without puberty and can describe what that absence actually entailed. His account covers emotional immaturity, social vulnerability, long-term health damage, and lasting fertility loss. What emerges from Linehan's testimony is that puberty is not simply a physical event that can be paused and resumed without consequence. Remaining in a childlike state while his peers matured left him, in his own account, more susceptible to manipulation and less capable of the autonomous judgement that adolescence ordinarily builds. The neurological and emotional development that puberty drives was absent, and the social isolation that resulted was not incidental — it was, he argues, a predictable and underestimated consequence. The episode gives substantial time to the question of fertility. Linehan is direct: his fertility was not recoverable. This is a matter the Cass Review examined closely. The independent review, published in April 2024 and commissioned by NHS England, found that claims of reversibility had been asserted with far greater confidence than the available research could justify. It noted that the long-term consequences of puberty suppression — on bone density, fertility, and neurological development — had not been adequately studied before GnRH analogues became a routine clinical offer. Linehan also addresses the relationship between puberty and brain maturation. Cognitive and emotional development does not proceed independently of the hormonal changes puberty brings; the two are deeply intertwined. Suppressing puberty, whether through a medical condition or pharmaceutical intervention, does not simply hold a child in place — it can alter the developmental trajectory in ways that are not straightforwardly reversed when treatment eventually begins. His testimony gives personal weight to what remained, in the clinical literature, largely a theoretical concern. NHS England ended the routine prescription of GnRH analogues to gender-questioning children following the Cass Review's conclusions, and the Tavistock Gender Identity Development Service closed in 2024. Scotland and Wales have since moved towards comparable restrictions. The reasoning behind those decisions — insufficient evidence, inadequate consent, uncertain long-term outcomes — is precisely what Linehan's experience illustrates. His warning to parents and clinicians is not that puberty suppression is categorically wrong in every medical context, but that deploying it routinely in a population that did not share his diagnosis carries risks that have not been honestly acknowledged.
